Natco Pharma to launch Pomalyst capsules in the Australian Market

Pomalyst (pomalidomide) Capsules in 1, 2, and 3 mg dosages will now be available in Australia thanks to NATCO Pharma Limited. Juno Pharmaceuticals Pty Ltd, NATCO’s business partner, introduced the product. Pomalidomide is prescribed to treat Multiple Myeloma and Kaposi Sarcoma, according to the filing. Refer to the complete prescribing information or other medical sources for more details.

According to data on industry sales, Pomalyst reported sales of USD 35.6 million in the Australian market for the year ending March 31st, 2022.

Shopping Cart
Scroll to Top